Pregnancy outcome following first-trimester exposure to zopiclone a
Am J Perinatol. 1999;16(4):157-60. Pregnancy outcome following first-trimester exposure to zopiclone: a prospective controlled cohort study. Diav-Citrin O(1).
Pregnancy outcome was compared with that of a matched control group of women, who were counseled for nonteratogenic exposure. The Motherisk Program, the Toronto Teratogen Information Service, prospectively collected and followed up 40 women exposed to zopiclone during pregnancy.
The purpose of this study was to compare pregnancy outcome following first-trimester exposure to zopiclone with that of a matched control group of women, who were counseled for nonteratogenic exposure. To date, no published data exist regarding human pregnancy experience with zopiclone. Zopiclone, a cyclopyrrolone derivative, is a short-acting hypnotic.
1 of 37 for nonteratogenic controls; p = 1). There was no increase in the rate of major malformations (0 of 31 for zopiclone vs.
National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.
Generate a file for use with external citation management software.
Larger studies are needed to establish its safety during pregnancy. Our study, which is the first cohort on zopiclone use during embryogenesis, albeit small, suggests that zopiclone does not appear to be a major human teratogen.